Agilent Technologies stock has delivered a 27.4% return over the past three years, while its valuation checks now show a split picture where the Discounted Cash Flow (DCF) intrinsic value points to upside and the market multiples look less generous.

• Over the past three years, Agilent Technologies returned 27.4%, which puts recent gains and today’s valuation in sharper focus for long term holders.
• The expanded EU approval for Agilent Technologies’ PD-L1 diagnostic test can support expectations for its diagnostics franchise, while competition from larger peers may limit how much investors are willing to pay for that growth.
• Agilent Technologies scores 3 out of 6 on the broader valuation checks, which is a mixed picture rather than a clear bargain or clear overvaluation, as shown in 3/6 valuation checks.

The stock’s next move may depend on whether investors put more weight on the DCF view that suggests the shares trade about 16.8% below intrinsic value or on the earnings multiples that indicate the stock already carries a premium.

Is Agilent Technologies Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model estimates what Agilent Technologies is worth today based on its expected future cash generation. Agilent Technologies produced about $1.06b in free cash flow over the latest twelve months, and the model assumes those cash flows continue growing rather than shrinking, using a two-stage forecast that tapers to more modest growth over time.

On these assumptions, the DCF model arrives at an estimated intrinsic value of about $178 per share, which is roughly 16.8% above the current share price, so the stock screens as undervalued on this method. The recent expansion of EU approval for Agilent Technologies’ PD-L1 diagnostic test in ovarian cancer helps explain why some investors may see room for that cash flow growth to continue despite strong competition in life sciences tools.

On the DCF view, Agilent Technologies stock currently looks undervalued relative to the cash flows analysts expect it to generate.

Our Discounted Cash Flow (DCF) analysis suggests Agilent Technologies is undervalued by 16.8%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Is Agilent Technologies Getting Expensive on Earnings?

The P/E ratio fits Agilent Technologies well because earnings are a key focus for investors in established life sciences businesses. Agilent Technologies currently trades on a P/E of about 29.7x, which is below the Life Sciences industry average of roughly 36.8x and also below the peer group average of about 34.6x.

However, the modelled fair P/E for Agilent Technologies, which reflects its earnings profile, industry position and risk, is closer to 24.1x. That is a clear gap to the current 29.7x multiple, so even with a discount to peers, the stock appears expensive relative to what this framework suggests investors might usually pay for its earnings.

On this P/E yardstick, Agilent Technologies stock appears overvalued compared with the multiple the model indicates as reasonable for its earnings power.

The Agilent Technologies Narrative: What Would Justify Today's Price?

Simply Wall St Narratives help you connect Agilent Technologies' current valuation puzzle with the specific expectations that would need to play out on growth, margins and earnings for the stock to be worth materially more or less than today’s price. Rather than focusing on a single multiple or model output, each narrative lays out the assumptions behind its fair value so you can later compare those to the company’s actual results.

Be one of the first voices in the Simply Wall St community to set out a clear, number driven narrative on Agilent Technologies and whether the expanded EU approval for its PD-L1 diagnostic test in ovarian cancer ultimately supports today's pricing. Share your view now and track how your thesis holds up as Agilent Technologies' results and diagnostics progress are reported over time.

Do you think there's more to the story for Agilent Technologies? Head over to our Community to see what others are saying!

The Bottom Line

Agilent Technologies sits in the middle ground where the Discounted Cash Flow (DCF) view suggests undervaluation, while earnings multiples point to an overvalued stock. That split reflects a clash between what its long term cash generation could support and what the market is already paying for near term growth and sentiment. The mixed broader valuation checks underline that neither signal is strong enough on its own. The real hinge from here is whether Agilent Technologies can deliver the earnings and cash flow to close that gap without investors pushing the multiple down.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.